Stryker Corp

SYK remains in a Stage 2 advancing phase with bullish medium- and long-term biases anchored by a clear higher-high/lower-low structure, but short-term conditions are neutral as price churns around flat EMAs after recent overbought extremes and shows signs of waning upside momentum. Execution is deferred—look to buy on pullbacks into rising EMAs and the support zone near prior swing lows.

• ↑Q1 organic sales rose 10.1% YoY; full-year organic growth guidance lifted to 8–9.5%.
• ↑Adjusted EPS hit $2.84 (+13.6% YoY); gross margin improved to 65.5%, operating margin to 22.9%.
• ↓Cyber breach disrupted operations, slowing medical segment sales rebound.